Moderna beat earnings expectations but its norovirus vaccine trial hit a wall

The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower

Moderna beat Wall Street estimates for second-quarter revenue on Friday benefiting from better-than-expected sales of its COVID-19 vaccine, as the company gears up for the potential launch of its flu shot.

Moderna Says Norovirus Vaccine Didn’t Meet Statistical Criteria for Early Success in Trial  WSJ

Investors were disappointed by the neobank’s restrained guidance.

Most U.S. stocks are rising after Coca-Cola and other companies reported stronger profits for the spring than analysts expected

UPS beat Wall Street expectations and raised its full-year guidance in its second-quarter earnings report Tuesday.